Compare UPBD & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPBD | BHVN |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.4B |
| IPO Year | 1996 | 2022 |
| Metric | UPBD | BHVN |
|---|---|---|
| Price | $17.32 | $8.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $32.25 | $29.08 |
| AVG Volume (30 Days) | 783.4K | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 8.25% | N/A |
| EPS Growth | N/A | ★ 26.08 |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $4,695,061,000.00 | N/A |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $6.47 | N/A |
| P/E Ratio | $29.51 | ★ N/A |
| Revenue Growth | ★ 8.67 | N/A |
| 52 Week Low | $15.82 | $7.48 |
| 52 Week High | $28.03 | $18.57 |
| Indicator | UPBD | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 35.51 | 41.69 |
| Support Level | $17.05 | $8.08 |
| Resistance Level | $19.26 | $10.57 |
| Average True Range (ATR) | 0.78 | 0.69 |
| MACD | -0.20 | -0.10 |
| Stochastic Oscillator | 8.97 | 7.25 |
Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has four operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions, Mexico segment offers lease-to-own stores in Mexico. The The Brigit segment offers various financial health products and tools to help users improve their financial health. The company derives a majority of its revenue from the Acima segment.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.